



# Covid-19 Story: Challenges & Opportunities for IVD Developers

Presented by: Averouz Maritz


Quality Assurance and Regulatory Affairs

# Company Background

- Medical Diagnostech (Pty) Ltd was established in 2010 as a developer and manufacturer of lateral flow rapid diagnostic test kits.
- We manufacture high quality rapid diagnostic test kits, using our trade secret methodology for increased sensitivity and early detection.



# Complete Global Disruption 2020



# CHALLENGES?

- 1. Development
- 2. Regulatory Approval
- 3. Marketing



# 1. Development

- ▶ Getting COVID positive samples
  - ▶ Because the virus was new, no institutions were willing to share samples, especially if you did not have ethical clearance
- ▶ Thus, we had to first obtain ethical clearance and a GCP certificate to engage with hospitals and patients
- ▶ Delays in logistics impacted existing production
- ▶ Not enough local funding made available for development



## 2. Regulatory Approval

- ▶ Initial communication was poor with SAHPRA (however, this improved in late 2021)
- ▶ Mis-communication between SAHPRA and the NRL.
  - ▶ The NRL validates IVDs on behalf of SAHPRA for regulatory approval
- ▶ The costs of IVD validation at the NRL was very expensive and slow
- ▶ No home testing allowed
- ▶ Slow regulatory reaction impacted viral spread



**SAHPRA**  
South African  
Health Products  
Regulatory Authority

## 3. Marketing

- Our Covid-19 Antigen test was only approved by SAHPRA in December 2021



# IF HINDSIGHT WAS 20/20

- ▶ SAHPRA has only begun to enforce the need for manufacturing companies to apply for a validation license at an NRL in the last three years
  - ▶ Covid pandemic caused a lot of confusion
- ▶ SAHPRA requirements for IVD product marketing for public tender market keeps changing
  - ▶ First they communicated that locally manufactured IVDs only needs SAHPRA approval
  - ▶ Next they communicated that WHO-PQ is also a requirement
- ▶ The goal posts for local manufacturers keep shifting
  - ▶ Making it difficult to take part in the supply of IVDs
- ▶ Foreign products flooded the market due to non-existent import tariffs or duties
  - ▶ Zero market localization had a negative impact on local companies



# RECOMMENDATIONS

- ▶ NRAs should re-evaluate approval of locally manufactured products vs imported product
  - ▶ WHO-PQ requirements on top of SAHPRA approval?
  - ▶ However, WHO-PQ for imported IVDs is reasonable
- ▶ Improving public-private communication and relationships during regulatory matters and national procurement regulations



